Brief: Hansa Biopharma Total Q1 Revenue Of SEK 24.2 Mln
20/04/2023 07:07
April 20 (Reuters) - Hansa Biopharma AB HNSA.ST :
* TOTAL Q1 REVENUE OF SEK 24.2M INCLUDING SEK 14.3M IN
PRODUCT
SALES AND SEK 9.9M IN REVENUE RECOGNITION MAINLY UNDER AGREEMENT
WITH SAREPTA
Source text for Eikon: ID:nWkr69bVzQ
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS